Related references
Note: Only part of the references are listed.A Novel Necroptosis-Related miRNA Signature for Predicting the Prognosis of Breast Cancer Metastasis
Lin Zheng et al.
DISEASE MARKERS (2022)
Necroptosis-related lncRNA to establish novel prognostic signature and predict the immunotherapy response in breast cancer
Fangyue Chen et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer
Lin He et al.
CANCERS (2021)
Necroptosis-Related lncRNAs: Predicting Prognosis and the Distinction between the Cold and Hot Tumors in Gastric Cancer
Zirui Zhao et al.
JOURNAL OF ONCOLOGY (2021)
Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis
Chundi Gao et al.
FRONTIERS IN IMMUNOLOGY (2021)
Role of necroptosis in infection-related, immune-mediated, and autoimmune skin diseases
Lulu Liu et al.
JOURNAL OF DERMATOLOGY (2021)
Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers
Sarah Bryan et al.
CANCERS (2021)
TNFSF9 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Pancreatic Cancer
Jiao Wu et al.
JOURNAL OF GASTROINTESTINAL CANCER (2021)
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers
Tim Kong et al.
CANCER RESEARCH (2020)
Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma
Chuanjie Zhang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients
Gongmin Zhu et al.
AGING-US (2020)
Triple-negative breast cancer-Role of immunology: A systemic review
Gizem Oner et al.
BREAST JOURNAL (2020)
Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors
Jia'nan Cheng et al.
ONCOLOGY LETTERS (2020)
Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer
Fangfang Bi et al.
CANCER CELL INTERNATIONAL (2020)
Triple-negative breast cancer therapy: Current and future perspectives (Review)
Kwang-Ai Won et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database
Jinhui Liu et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2020)
Death by inflammation: drug makers chase the master controller
Cormac Sheridan
NATURE BIOTECHNOLOGY (2019)
Death by inflammation: drug makers chase the master controller (vol 37, pg 111, 2019)
Cormac Sheridan
NATURE BIOTECHNOLOGY (2019)
RIP1 kinase inhibitor halts the progression of an immune-induced demyelination disease at the stage of monocyte elevation
Sitao Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The role of necroptosis in cancer biology and therapy
Yitao Gong et al.
MOLECULAR CANCER (2019)
Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity
Annelise G. Snyder et al.
SCIENCE IMMUNOLOGY (2019)
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Qingzhu Jia et al.
JCI INSIGHT (2019)
Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer
Ding Ren et al.
CANCER RESEARCH (2018)
Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications
Ruth Chia et al.
LANCET NEUROLOGY (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance
Sonia Palomeras et al.
MOLECULES (2018)
Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes
Lien Van Hoecke et al.
NATURE COMMUNICATIONS (2018)
Resistance of primary breast cancer cells with enhanced pluripotency and stem cell activity to sex hormonal stimulation and suppression
Mostafa Nasr et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)
Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks
Endre Sebestyen et al.
GENOME RESEARCH (2016)
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression
Lena Seifert et al.
NATURE (2016)
Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis
Boris Strilic et al.
NATURE (2016)
RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS
Yasushi Ito et al.
SCIENCE (2016)
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Immunity, Inflammation, and Cancer
Sergei I. Grivennikov et al.
CELL (2010)
Necroptosis as an alternative form of programmed cell death
Dana E. Christofferson et al.
CURRENT OPINION IN CELL BIOLOGY (2010)
Signaling Through OX40 Enhances Antitumor Immunity
Shawn M. Jensen et al.
SEMINARS IN ONCOLOGY (2010)
Identification of RIP1 kinase as a specific cellular target of necrostatins
Alexei Degterev et al.
NATURE CHEMICAL BIOLOGY (2008)